Combination treatment with varenicline and nicotine replacement therapy / Jon O. Ebbert (2009)

Public Titre : Combination treatment with varenicline and nicotine replacement therapy Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Michael V. Burke, Auteur ; Richard D. Hurt, Auteur Editeur : Oxford University Press Année de publication : 2009 Collection : Nicotine and Tobacco Research num. Vol 11, n. 5 Importance : p. 572-576 Langues : Anglais (eng) Catégories : [TABAC] étude [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract INTRODUCTION: A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT). METHODS: We reviewed the clinical experience of two groups of cigarette smokers enrolled in a residential tobacco treatment program: (a) patients receiving combination treatment with varenicline and NRT (N = 104) and (b) usual-care patients receiving treatment before the release of varenicline (N = 135). RESULTS: Demographic characteristics were similar between the two groups. Among smokers receiving varenicline and NRT, 71% used the nicotine patch with a mean dose of 32 mg/day (SD = 14) and 73% used at least two types of NRT. Adverse events were experienced by 39% (95% CI = 31%-49%) of patients receiving varenicline and NRT and by 59% (95% CI = 51%-67%) of usual-care patients during the residential program. A total of five patients (5%) discontinued varenicline due to adverse events, compared with one patient in the usual-care group. We did not observe a significant difference in the 30-day point prevalence smoking abstinence rate at 6 months between patients treated with varenicline and NRT (54%; 95% CI = 44%-64%) and usual-care patients (59%; 95% CI = 50%-66%). DISCUSSION: Our findings suggest that combination therapy with varenicline and NRT is safe and well tolerated among patients in a residential tobacco treatment program. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7950

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005491	TA 6.2.3.1.4 EBB C	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

A comparison of sustained-release bupropion and placebo for smoking cessation / Richard D. Hurt (1997)  

Public Titre : A comparison of sustained-release bupropion and placebo for smoking cessation Type de document : texte imprimé Auteurs : Richard D. Hurt, Auteur ; David P.L. Sachs, Auteur ; Elbert T. Glover, Auteur ; Kenneth P. Offord, Auteur Editeur : Massachusetts Medical Society Année de publication : 1997 Collection : New England Journal of Medicine num. 337:17 Importance : p. 1195-1202 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude [TABAC] étude:recherche:recherche clinique:essai clinique randomisé [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placebo Index. décimale : TA 6.2.3.2 Autres produits Résumé : BACKGROUND AND METHODS: Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or "target quit date") was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less. RESULTS: At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P=0.02) and the 300-mg group (P=0.01) -- but not the 100-mg group (P=0.09) -- were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P= 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups. CONCLUSIONS: A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year. En ligne : https://www.nejm.org/doi/10.1056/NEJM199710233371703?url_ver=Z39.88-2003&rfr_id= [...] Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8138

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Recent advances in the pharmacotherapy of smoking / John R. Hughes (1999)

Public Titre : Recent advances in the pharmacotherapy of smoking Type de document : texte imprimé Auteurs : John R. Hughes, Auteur ; Michael G. Goldstein, Auteur ; Richard D. Hurt, Auteur ; Saul Shiffman, Auteur Editeur : American Medical Association (AMA) Année de publication : 1999 Collection : JAMA : Journal of the American Medical Association num. 281 (1) Importance : p.72-76 Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:pharmacologie [TABAC] sevrage tabagique [TABAC] tabagisme Index. décimale : TA 6.2.3 Approche pharmacologique Résumé : Since the 1996 publication of guidelines on smoking cessation from the Agency for Health Care Policy and Research and the American Psychiatric Association, several new treatments have become available, including nicotine nasal spray, nicotine inhaler, and bupropion hydrochloride. In addition, nicotine gum and patch have become available over-the-counter. This article reviews the published literature and US Food and Drug Administration and pharmaceutical company reports on these therapies. Based on this review, clinical logic, and experience, we conclude that pharmacotherapy should be made available to all smokers. All currently available therapies appear to be equally efficacious, approximately doubling the quit rate compared with placebo. Concomitant behavioral or supportive therapy increases quit rates and should be encouraged but not required. Combining patch with gum or patch with bupropion may increase the quit rate compared with any single treatment. Because patient characteristics predictive of success with a particular therapy are not yet known, the best treatment choice for an individual patient should be guided by the patient's past experience and preference and the product's adverse effect profile. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2588

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 002334	TA 6.2.3. HUH R	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Waking a Sleeping Giant / Monique E. Muggli (01/09/2008)  

Public Titre : Waking a Sleeping Giant : The Tobacco Industry’s Response to the Polonium-210 Issue Type de document : texte imprimé Auteurs : Monique E. Muggli, Auteur ; Jon O. Ebbert, Auteur ; Channing Robertson, Auteur ; Richard D. Hurt, Auteur Editeur : Alpha Press Année de publication : 01/09/2008 Collection : American Journal of Public Health num. 98 (9) Importance : p.1643-1650 Note générale : Dans la bibliothèque virtuelle (articles scientifiques) Catégories : [TABAC] chimie du tabac:constituant:additif [TABAC] chimie du tabac:fumée:polonium [TABAC] chimie du tabac:substance toxique Index. décimale : TA 1.4 Additifs Résumé : The major tobacco manufacturers discovered that polonium was part of tobacco and tobacco smoke more than 40 years ago and attempted, but failed, to remove this radioactive substance from their products. Internal tobacco industry documents reveal that the companies suppressed publication of their own internal research to avoid heightening the public’s awareness of radioactivity in cigarettes. Tobacco companies continue to minimize their knowledge about polonium- 210 in cigarettes in smoking and health litigation. Cigarette packs should carry a radiation-exposure warning label. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2509609/ Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1444

Aucun avis, veuillez vous identifier pour ajouter le vôtre !